Co-Founder, CEO

With an illustrious academic career spanning over two decades, Dr. Kweh has dedicated herself to the pursuit of scientific knowledge and improving patient health outcomes. Her expertise in immunology, cardiovascular disease, infectious diseases, and cancer research has led to groundbreaking discoveries. Notably, her research has shed light on the link between periodontal disease and cardiovascular disease, explored potential treatments for dental caries, and unraveled the role of vitamin D signaling in monocytes. Furthermore, she has spearheaded cutting-edge investigations into therapy resistance in non-Hodgkin lymphomas, delving into the complexities of drug resistance and addiction in T-lymphocyte cancers. Her unwavering goal has been to develop innovative treatment approaches that can be evaluated in clinical trials, ultimately reducing the mortality rate associated with lymphomas. Fueled by a deep commitment to effecting positive change through translational research, Dr. Kweh made a bold career transition from academia to the biotech industry.

 As the Director of Clinical Translation in a specialized biotech company focused on regenerative medicine, she swiftly recognized the immense potential of regenerative science in managing complex diseases across various medical domains, surgical interventions, and rehabilitative practices. However, she also became acutely aware of the alarming proliferation of untested treatments offered by clinics within the rapidly expanding regenerative medicine market. This concerning trend has raised significant apprehensions among scientists and ethicists, primarily due to the absence of scientific evidence substantiating the efficacy of these therapies. Driven by a sense of urgency, Dr. Kweh identified critical issues that demanded attention in this nascent field, including patient safety, the potential dismissal of valid therapies, and the erosion of public and investor trust.

Driven by an unwavering desire to bring about positive changes in the field of regenerative medicine, Dr. Kweh founded KweHealth. This pioneering TechBio company envisions a transformative landscape for the exploration, advancement, and application of exosome-based regenerative biotherapeutics in the management of intractable diseases. With a mission to assist regenerative medicine researchers and clinicians, KweHealth also provides invaluable support in writing and submitting case studies, Investigational New Drug (IND) applications, and Institutional Review Board (IRB) approvals. Harnessing the power of advanced analytics, automation, machine learning, and artificial intelligence, KweHealth gathers robust real-world data that validates the efficacy and safety of regenerative therapies. Moreover, KweHealth aims to revolutionize patient participation and experience in regenerative medicine clinical trials through the utilization of wearable devices and smart technologies. By doing so, KweHealth empowers stakeholders with valuable insights into the safety and effectiveness of these transformative therapies.